Fresh Tracks Therapeutics, Inc. (FRTX)

OTCMKTS: FRTX · Delayed Price · USD
0.900
+0.020 (2.26%)
Apr 16, 2024, 10:20 AM EDT - Market open
Market Cap 5.38M
Revenue (ttm) 8.01M
Net Income (ttm) -5.63M
Shares Out 5.97M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,407
Open 0.900
Previous Close 0.880
Day's Range 0.900 - 0.900
52-Week Range 0.450 - 1.100
Beta 0.49
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2023

About FRTX

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol FRTX
Full Company Profile

Financial Performance

In 2023, FRTX's revenue was $8.01 million, an increase of 15.31% compared to the previous year's $6.94 million. Losses were -$5.69 million, -72.44% less than in 2022.

Financial Statements

News

Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024

2 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th

New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, wh...

3 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Listing on OTC Pink Market

BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspended from ...

4 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th

Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension

4 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders

Meeting adjourned to December 27, 2023 at 10 a.m. MT

4 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders

Meeting adjourned to December 15, 2023 at 10 a.m. MT

4 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders

Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.

5 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution I...

5 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution

Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of th...

7 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromi...

8 months ago - GlobeNewsWire

Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shar...

9 months ago - GlobeNewsWire

Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for at...

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company Rob Brown to continue serving as a member of the Board of Directors and as a special advisor...

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity

Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023 Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022

BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disru...

1 year ago - GlobeNewsWire

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing

1 year ago - GlobeNewsWire